Avutometinib + Defactinib

About Verastem Oncology

Verastem Oncology is a commercial-stage biotech company with a mission to develop novel treatments for RAS/MAPK pathway-driven cancers, a major oncogenic driver in ~30% of human cancers. Its key achievement is the FDA approval of avutometinib (a RAF/MEK clamp) combined with defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's strategy is built on a deep understanding of pathway biology, pursuing rational drug combinations to block primary drivers and compensatory resistance, and forging strategic partnerships to accelerate development in high-unmet-need oncology areas.

About Verastem Oncology

Verastem Oncology is a commercial-stage biotech company with a mission to develop novel treatments for RAS/MAPK pathway-driven cancers, a major oncogenic driver in ~30% of human cancers. Its key achievement is the FDA approval of avutometinib (a RAF/MEK clamp) combined with defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's strategy is built on a deep understanding of pathway biology, pursuing rational drug combinations to block primary drivers and compensatory resistance, and forging strategic partnerships to accelerate development in high-unmet-need oncology areas.

About Verastem Oncology

Verastem Oncology is a commercial-stage biotech company with a mission to develop novel treatments for RAS/MAPK pathway-driven cancers, a major oncogenic driver in ~30% of human cancers. Its key achievement is the FDA approval of avutometinib (a RAF/MEK clamp) combined with defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's strategy is built on a deep understanding of pathway biology, pursuing rational drug combinations to block primary drivers and compensatory resistance, and forging strategic partnerships to accelerate development in high-unmet-need oncology areas.

About Verastem Oncology

Verastem Oncology is a commercial-stage biotech company with a mission to develop novel treatments for RAS/MAPK pathway-driven cancers, a major oncogenic driver in ~30% of human cancers. Its key achievement is the FDA approval of avutometinib (a RAF/MEK clamp) combined with defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's strategy is built on a deep understanding of pathway biology, pursuing rational drug combinations to block primary drivers and compensatory resistance, and forging strategic partnerships to accelerate development in high-unmet-need oncology areas.

About Verastem Oncology

Verastem Oncology is a commercial-stage biotech company with a mission to develop novel treatments for RAS/MAPK pathway-driven cancers, a major oncogenic driver in ~30% of human cancers. Its key achievement is the FDA approval of avutometinib (a RAF/MEK clamp) combined with defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's strategy is built on a deep understanding of pathway biology, pursuing rational drug combinations to block primary drivers and compensatory resistance, and forging strategic partnerships to accelerate development in high-unmet-need oncology areas.

About Verastem Oncology

Verastem Oncology is a commercial-stage biotech company with a mission to develop novel treatments for RAS/MAPK pathway-driven cancers, a major oncogenic driver in ~30% of human cancers. Its key achievement is the FDA approval of avutometinib (a RAF/MEK clamp) combined with defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's strategy is built on a deep understanding of pathway biology, pursuing rational drug combinations to block primary drivers and compensatory resistance, and forging strategic partnerships to accelerate development in high-unmet-need oncology areas.

Therapeutic Areas